Original Research
Rev Panam Salud Publica 43, 2019 | www.paho.org/journal | https://doi.org/10.26633/RPSP.2019.31
Investigación original / Original research
Rev Panam Salud Publica 35(1), 2014
· Relevant interventions
· HIV country profiles
· Adolescents country profiles
Training for Health Care Providers
Facilitators’ Manual
Analyse des politiques et des programmes : opportunités et défis pour l’UNFPAseptembre
Le Bénin est un pays à épidémie mixte car il existe des poches de concentration de fortes prévalences
au sein de certaines populations clés plus exposées aux risques d’infection, notamment les TS et
leurs partenaires, les prisonniers, les HSH et les UDI. Les sections suivantes présentero...nt la
prévalence dans les différents groupes.
more
The report shows that where people and communities living with and affected by HIV are engaged in decision-making and HIV service delivery, new infections decline and more people living with HIV gain access to treatment. When people have the power to choose, to know, to thrive, to demand and to work... together, lives are saved, injustices are prevented and dignity is restored.
more
Policy Brief
Consolidated Guidelines
Updated 2016
WHO/HIV/2017.05
World Health Organization Department of Reproductive Health and Research
Brocher Foundation, Hermance, Geneva, Switzerland, 27–29 April 2016
Clinical Guidance across the continuum of care
Chapter 8_ARV Guidelines
“Continuum of HIV services refers to a comprehensive package of HIV prevention, diagnostic, treatment, care and support services provided for people at risk of HIV infection or living with HIV and their families”
August, 2018
The guidelines are aimed at clinical professionals directly involved with and responsible for the care of adults with HIV infection, and at community advocates responsible for promoting the best interests and care of HIV-positive adults. They should be read in conjunction with other published BHIVA ...guidelines.
The 2016 interim update to the 2015 BHIVA antiretroviral guidelines has been published online to include tenofovir-alafenamide/emtricitabine as a preferred NRTI backbone for first-line therapy. Changes were based on new data and the consensus opinion of the writing committee. All changes to the guideline are highlighted and include updates to the chronic kidney disease and bone disease sections of special populations and some small changes to managing virological failure.
The 2019 interim statement provides updated advice on treatment with two-drug regimens
more